An update on a 2015 report shows that gabapentinoid usage in the U.S. has continued to climb

Gabapentinoids are commonly prescribed for an array of off-label conditions, including management of chronic pain

2024-01-22

(Press-News.org) Gabapentinoids are commonly prescribed for an array of off-label conditions, including management of chronic pain. Updating their 2015 report on gabapentinoid usage in the U.S., researchers used the 2002–2021 Medical Expenditure Panel Survey (MEPS) to investigate the proportion of the adult population using gabapentinoids, medications, and diagnoses associated with users, and the likelihood of starting, stopping, or continuing gabapentinoids. They found that gabapentinoid use has increased from 4.0% in 2015 to 4.7% in 2021. Gabapentinoids continue to be used in conjunction with other sedating medications, despite a 2019 FDA warning against doing so. Although off-label use is difficult to connect with specific medical conditions and is likely under-reported, numerous chronic pain conditions remain associated with gabapentinoids. Between the survey periods of 2011–2012 and 2017–2018, the percentage of those continuing to use gabapentinoids year on year was greater than those who stopped, though this difference appears to have decreased more recently.

What We Know: Gabapentinoid prescription and use continues to increase in the U.S., from 4.0% in 2015 to 4.7% in 2021. Despite a 2019 FDA warning, gabapentinoids continue to be used in conjunction with other sedating medications.

What This Study Adds: Gabapentinoid users have continued to increase since the authors’ 2015 publication, despite a dearth of evidence supporting use in many cases. While these clinical scenarios can be challenging, continuation should be reconsidered at regular intervals.

Update to Gabapentinoid Use in the United States, 2002–2021

Michael E. Johansen, MD, MS

Grant Family Medicine, OhioHealth, Columbus, OH

Donovan T. Maust, MD, MS

Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI;

Department of Psychiatry, University of Michigan, Ann Arbor, MI

PRE-EMBARGO LINK (Link expires at 5 p.m. EDT Jan. 22, 2024)

PERMANENT LINK

END

ELSE PRESS RELEASES FROM THIS DATE:

The serious risks and high costs of monoclonal antibodies may outweigh the benefits for patients with Alzheimer dementia

2024-01-22

Researchers performed a meta-analysis of randomized trial studies that compared the use of amyloid-reducing monoclonal antibodies (MABs) in patients with Alzheimer dementia at a dose consistent with that used in Phase 3 or FDA approval trials with the use of a placebo. Their purpose was to evaluate clinically meaningful benefits and harms of MABs to these patients. For inclusion in this meta-analysis, the RCT studies had to include adult participants with cognitive impairment or Alzheimer disease of any severity and report at least one clinically relevant benefit or harm to participants after at least one year. The research team identified 19 such publications that evaluated ...

Annals of Family Medicine January/February 2024 Tip Sheet

2024-01-22

EHR Workload Continues to Grow for Primary Care Physicians The study evaluated recent trends in primary care physicians’ (PCPs) electronic health record (EHR) workload. Prior to and early in the COVID-19 pandemic, PCPs spent more time in the EHR and received more messages than physicians in other specialties, but it is unclear if the pandemic further accelerated the growth of PCPs’ EHR workload. Researchers observed EHR usage of 141 academic PCPs practicing family medicine, internal medicine, and general pediatrics within the University of Wisconsin-Madison health system, which ...

A quality improvement intervention links high-risk prenatal patients at safety-net health centers with primary care

2024-01-22

Researchers assessed the development and implementation of a quality improvement learning collaborative’s (QILC) intervention to link high-risk prenatal patients with primary care. The aims of the study were twofold: to identify any quantitative impact of the intervention on postpartum and primary care utilization for high-risk prenatal patients and to explore the Federally Qualified Health Center (FQHC) participants’ experiences of working with a QI collaborative. Using information from patients’ charts and/or ...

A new drug candidate can shrink kidney cysts

2024-01-22

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 million people worldwide, and many patients end up needing dialysis or a kidney transplant by the time they reach their 60s. Researchers at MIT and Yale University School of Medicine have now found that a compound originally developed as a potential cancer treatment holds promise for treating ADPKD. The drug works by exploiting kidney cyst cells’ vulnerability to oxidative stress — a state ...

Bone marrow adipocytes provide early sign of progression from MGUS to multiple myeloma

2024-01-22

A new research perspective was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.” Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the bone marrow. In spite of recent advances in the field of MM, the disease has remained incurable. MM is preceded by a premalignant state known as monoclonal gammopathy of undetermined significance (MGUS), with a risk of progression to MM of 1% per year. Establishing a scalable approach that refines ...

Dr. Blagosklonny’s battle with cancer (Part 1)

2024-01-22

On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.” “In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with ...

Don’t blame the sharks: Research led by UMass Amherst reveals why more hooked tarpon are being eaten

2024-01-22

In wave-making research recently published in Marine and Coastal Fisheries, a team of researchers, led by biologists at the University of Massachusetts Amherst, has quantified the rate at which great hammerhead sharks are eating Atlantic tarpon hooked by anglers at Bahia Honda, Florida—one of the prime tarpon fishing spots in the Florida Keys. Called the “depredation rate,” the team found that 15.3% of tarpon that were hooked by anglers and fought for more than five minutes were eaten while still on the line. But the researchers also show that this is not necessarily a sign that the ecosystem is out of balance. To the contrary, increased reports ...

Shallow soda lakes show promise as cradles of life on Earth

2024-01-22

Charles Darwin proposed that life could have emerged in a “warm little pond” with the right cocktail of chemicals and energy. A study from the University of Washington, published this month in Communications Earth & Environment, reports that a shallow “soda lake” in western Canada shows promise for matching those requirements. The findings provide new support that life could have emerged from lakes on the early Earth, roughly 4 billion years ago. Scientists have known that under ...

Computing with the power of light

2024-01-22

The exponential demand for high computing power is far exceeding the capabilities of current electronic systems; however, engineers at the University of Pittsburgh are shining a light on new solutions. Nathan Youngblood, principal investigator and assistant professor of electrical and computer engineering at Pitt’s Swanson School of Engineering, received a $552,166 Faculty Early Career Development Award from the National Science Foundation (NSF) and a $449,240 award from the Air Force Office of Scientific Research (AFOSR) through its Young Investigator Program (YIP) to continue his pioneering work in phase-change materials and optical computing. “Dr. ...

Cholangiocarcinoma: New organ-on-chip aims at accelerating research and personalized medicine

2024-01-22

Milano, January 22nd 2024 – It is only a few centimeters in size and can be held between two fingers, but in the micro-channels carved inside it, it’s hidden a three-dimensional and highly faithful model of a biliary tract cancer called cholangiocarcinoma, complete with its tumor microenvironment. This 3D model is built starting from a sample of patient’s cancer cells and thus it represents a patient-specific "organ-on-chip": a technology made possible only through a multidisciplinary approach that merges biomedicine, physics and engineering. The innovative prototype is the result ...